All In Biotech

Drug Trial Radar · NCT05143957

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Dec 30, 2021

Primary completion

Jun 26, 2025

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.

Conditions

  • Phlebotomy Dependent Polycythemia Vera

Interventions

  • sapablursenDrug

    Sapablursen will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment PeriodTime frame: Week 17 to Week 37

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Border Medical Oncology Research Unit

    Albury, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku

    Lublin, Poland

  • Wojewódzki Szpital Specjalistyczny Sp. z o.o.

    Słupsk, Poland

  • MICS Centrum Medyczne Toruń

    Torun, Poland

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.